<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35214599</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">140</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10020140</ELocationID><Abstract><AbstractText>The vaccination program is reducing the burden of COVID-19. However, recently, COVID-19 infections have been increasing across Europe, providing evidence that vaccine efficacy is waning. Consequently, booster doses are required to restore immunity levels. However, the relative risk-benefit ratio of boosters, compared to pursuing a primary course in the unvaccinated population, remains uncertain. In this study, a susceptible-exposed-infectious-recovered (SEIR) transmission model of SARS-CoV-2 was used to investigate the impact of COVID-19 vaccine waning on disease burden, the benefit of a booster vaccine program compared to targeting the unvaccinated population, and the population-wide risk-benefit profile of vaccination. Our data demonstrates that the rate of vaccine efficacy waning has a significant impact on COVID-19 hospitalisations with the greatest effect in populations with lower vaccination coverage. There was greater benefit associated with a booster vaccination strategy compared to targeting the unvaccinated population, once &gt;50% of the population had received their primary vaccination course. The population benefits of vaccination (reduced hospitalisations, long-COVID and deaths) outweighed the risks of myocarditis/pericarditis by an order of magnitude. Vaccination is important in ending the COVID-19 pandemic sooner, and the reduction in hospitalisations, death and long-COVID associated with vaccination significantly outweigh any risks. Despite these obvious benefits some people are vaccine reluctant, and as such remain unvaccinated. However, when most of a population have been vaccinated, a focus on a booster vaccine strategy for this group is likely to offer greater value, than targeting the proportion of the population who choose to remain unvaccinated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shiri</LastName><ForeName>Tinevimbo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Diabetes Resource Centre, University Hospital Llandough, Cardiff CF64 2XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarico</LastName><ForeName>Carla A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Angharad R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussad</LastName><ForeName>Maaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ashfield Healthcare on Behalf of Moderna, Ashby-de-la-Zouch LE65 1HW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Philip O</ForeName><Initials>PO</Initials><Identifier Source="ORCID">0000-0002-3898-3669</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>Phil</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd., Cardiff CF23 8RB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>William David</ForeName><Initials>WD</Initials><Identifier Source="ORCID">0000-0002-6826-418X</Identifier><AffiliationInfo><Affiliation>Diabetes and Vascular Research Centre, University of Exeter Medical School, Exeter EX1 2HZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Academic Department of Healthcare for Older Adults, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Moderna Therapeutics (United States)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">boosters</Keyword><Keyword MajorTopicYN="N">modelling</Keyword><Keyword MajorTopicYN="N">population risk</Keyword></KeywordList><CoiStatement>T.S., A.R.M. and P.M. are employees of Health Economics and Outcomes Research Ltd., Cardiff, UK. Health Economics and Outcomes Research Ltd. received fees from Moderna in relation to this study. C.A.T. and P.O.B. are employees of Moderna, Inc. and hold Moderna stocks/stock options. M.M. is an employee of Ashfield Healthcare on behalf of Moderna and does not hold stocks/ stock options. M.E. and W.D.S. have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35214599</ArticleId><ArticleId IdType="pmc">PMC8880242</ArticleId><ArticleId IdType="doi">10.3390/vaccines10020140</ArticleId><ArticleId IdType="pii">vaccines10020140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon L., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., C&#xe1;rdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Krutikov M., Palmer T., Giddings R., Azmi B., Subbarao S., Fuller C., Irwin-Singer A., Davies D., Tut G., et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study. Lancet Infect. Dis. 2021;21:1529&#x2013;1538. doi: 10.1016/S1473-3099(21)00289-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00289-9</ArticleId><ArticleId IdType="pmc">PMC8221738</ArticleId><ArticleId IdType="pubmed">34174193</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustsen-Helms I.R., Emborg H.-D., Nielsen J., Nielsen K.F., Krause T.G., M&#xf8;lbak K., M&#xf8;ller K.L., Berthelsen A.-S.N., Valentiner-Branth P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers&#x2014;A Danish cohort study. medRxiv. 2021 doi: 10.1101/2021.03.08.21252200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.08.21252200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.J., Foulkes S., Saei A., Andrews N., Oguti B., Charlett A., Wellington E., Stowe J., Gillson N., Atti A., et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. Lancet. 2021;397:1725&#x2013;1735. doi: 10.1016/S0140-6736(21)00790-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00790-X</ArticleId><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hern&#xe1;n M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 2021;384:1412&#x2013;1423. doi: 10.1056/NEJMoa2101765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodick G., Tene L., Patalon T., Gazit S., Tov A.B., Cohen D., Muhsen K. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw. Open. 2021;4:e2115985. doi: 10.1001/jamanetworkopen.2021.15985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.15985</ArticleId><ArticleId IdType="pmc">PMC8185600</ArticleId><ArticleId IdType="pubmed">34097044</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., Mandelboim M., Levin E.G., Rubin C., Indenbaum V., et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 2021;385:1474&#x2013;1484. doi: 10.1056/NEJMoa2109072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109072</ArticleId><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Lee J., Ta C., Soroush A., Rogers J.R., Kim J.H., Natarajan K., Zucker J., Weng C. A retrospective analysis of COVID-19 mRNA vaccine breakthrough infections&#x2014;Risk factors and vaccine effectiveness. medRxiv. 2021 doi: 10.1101/2021.10.05.21264583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.05.21264583</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.M., Vostok J., Johnson H., Burns M., Gharpure R., Sami S., Sabo R.T., Hall N., Foreman A., Schubert P.L., et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings&#x2014;Barnstable County, Massachusetts, July 2021. Morb. Mortal. Wkl. Rep. 2021;70:1059&#x2013;1062. doi: 10.15585/mmwr.mm7031e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7031e2</ArticleId><ArticleId IdType="pmc">PMC8367314</ArticleId><ArticleId IdType="pubmed">34351882</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency  SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 28.  [(accessed on 12 November 2021)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1033101/Technical_Briefing_28_12_Nov_2021.pdf.</Citation></Reference><Reference><Citation>Ai J., Zhang H., Zhang Y., Lin K., Wu J., Wan J., Huang Y., Song J., Fu Z., Wang H., et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microb. Infect. 2021;22:1&#x2013;24. doi: 10.1080/22221751.2021.2022440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2022440</ArticleId><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub P.P., Al Kanaani Z., et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 2021;385:e38. doi: 10.1056/NEJMoa2114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Fischer H., Hong V., Ackerson B.K., Ranasinghe O.N., Frankland T.B., Ogun O.A., Zamparo J.M., Gray S., et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet. 2021;398:1407&#x2013;1416. doi: 10.1016/S0140-6736(21)02183-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02183-8</ArticleId><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., Ferreira I.A.T.M., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., Meng B., Abdullahi A., Elmer A., Kingston N., et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417&#x2013;422. doi: 10.1038/s41586-021-03739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03739-1</ArticleId><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. Covid-19: Protection from two doses of vaccine wanes within six months, data suggest. BMJ. 2021;374:n2113. doi: 10.1136/bmj.n2113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2113</ArticleId><ArticleId IdType="pubmed">34433543</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry E., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruxvoort K.J., Sy L.S., Qian L., Ackerson B.K., Luo Y., Lee G.S., Tian Y., Florea A., Aragones M., Tubert J.E., et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: Test negative case-control study. BMJ. 2021;375:e068848. doi: 10.1136/bmj-2021-068848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068848</ArticleId><ArticleId IdType="pmc">PMC8671836</ArticleId><ArticleId IdType="pubmed">34911691</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters.  [(accessed on 20 November 2021)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Overview of COVID-19 Vaccine Recommendations.  [(accessed on 20 November 2021)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#overview-covid19-vax-recommendations.</Citation></Reference><Reference><Citation>Wise J. Covid-19: Booster doses to be offered to 30 million people in UK. BMJ. 2021;374:n2261. doi: 10.1136/bmj.n2261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2261</ArticleId><ArticleId IdType="pubmed">34521637</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK  Press Release: JCVI Issues Updated Advice on COVID-19 Booster Vaccination.  [(accessed on 20 November 2021)]; Available online:  https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-booster-vaccination.</Citation></Reference><Reference><Citation>GOV.UK  Press Release: JCVI Issues Advice on COVID-19 Booster Vaccines for Those Aged 40 to 49 and Second Doses for 16 to 17 Year Olds.  [(accessed on 20 November 2021)]; Available online:  https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-booster-vaccines-for-those-aged-40-to-49-and-second-doses-for-16-to-17-year-olds.</Citation></Reference><Reference><Citation>University Hospital Southampton NHS Foundation Trust  COV-Boost Vaccine Trial.  [(accessed on 20 November 2021)].  Available online:  https://www.covboost.org.uk/home.</Citation></Reference><Reference><Citation>National Institute for Health Research  Data from NIHR-Supported Studies Inform UK COVID-19 Booster Programme.  [(accessed on 20 November 2021)].  Available online:  https://www.nihr.ac.uk/news/data-from-nihr-supported-studies-inform-uk-covid-19-booster-programme/28663.</Citation></Reference><Reference><Citation>Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., Mizrahi B., Alroy-Preis S., Ash N., Milo R., et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393&#x2013;1400. doi: 10.1056/NEJMoa2114255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause A.M., Baggs J., Gee J., Marquez P., Myers T.R., Shimabukuro T.T., Shay D.K. Safety monitoring of an additional dose of COVID-19 vaccine&#x2014;United States, August 12&#x2013;September 19, 2021. Morb. Mortal. Wkly. Rep. 2021;70:1379&#x2013;1384. doi: 10.15585/mmwr.mm7039e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7039e4</ArticleId><ArticleId IdType="pmc">PMC8486391</ArticleId><ArticleId IdType="pubmed">34591835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory committee on immunization practices&#x2014;United States, June 2021. Morb. Mortal. Wkly. Rep. 2021;70:977&#x2013;982. doi: 10.15585/mmwr.mm7027e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7027e2</ArticleId><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 Subcommittee on Reports of Guillain-Barr&#xe9; Syndrome (GBS) Following Adenovirus Vector COVID-19 Vaccines.  [(accessed on 20 November 2021)].  Available online:  https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs.</Citation></Reference><Reference><Citation>Lai C.-C., Ko W.-C., Chen C.-J., Chen P.-Y., Huang Y.-C., Lee P.-I., Hsueh P.-R. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Rev. Vaccines. 2021;20:1027&#x2013;1035. doi: 10.1080/14760584.2021.1949294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1949294</ArticleId><ArticleId IdType="pubmed">34176415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiri T., Evans M., Talarico C.A., Morgan A.R., Mussad M., Buck P.O., McEwan P., Strain W.D. Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: A population-based modeling study using the UK as an example. Vaccines. 2021;9:1180. doi: 10.3390/vaccines9101180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101180</ArticleId><ArticleId IdType="pmc">PMC8537561</ArticleId><ArticleId IdType="pubmed">34696288</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK  Vaccinations in United Kingdom 2021.  [(accessed on 20 November 2021)]; Available online:  https://coronavirus.data.gov.uk/details/vaccinations.</Citation></Reference><Reference><Citation>GOV.UK  Coronavirus (COVID-19) in the UK 2021.  [(accessed on 20 November 2021)]; Available online:  https://coronavirus.data.gov.uk/details/cases.</Citation></Reference><Reference><Citation>Our World in Data  Daily New Confirmed COVID-19 Cases.  [(accessed on 20 November 2021)].  Available online:  https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&amp;time=2020-06-09..&amp;country=GBR~DEU~FRA~ITA~BEL~AUT~FIN~HUN~IRL~SWE~ESP~SVK~SVN~ROU~PRT~POL~NOR~NLD~LUX~LTU~MLT~LVA~LIE~ISL~GRC~DNK~CYP~HRV&amp;region=Europe&amp;pickerMetric=location&amp;pickerSort=asc&amp;tab=map&amp;yScale=log&amp;Interval=New+per+day&amp;Align+outbreaks=true&amp;Relative+to+Population=false&amp;Metric=Confirmed+cases.</Citation></Reference><Reference><Citation>GOV.UK  Coronavirus in the Vaccinated in the UK 2022.  [(accessed on 4 January 2022)]; Available online:  https://www.gov.uk/government/publications/coronavirus-press-conferences-quality-and-methodology-information-report.</Citation></Reference><Reference><Citation>Strain W.D., Mansi J., Boikos C., Boivin M., Fisher W.A. Achieving influenza vaccine uptake target in Canada via a pharmacy-led telephone discussion during the 2019&#x2013;2020 season. Vaccines. 2021;9:312. doi: 10.3390/vaccines9040312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9040312</ArticleId><ArticleId IdType="pmc">PMC8065524</ArticleId><ArticleId IdType="pubmed">33810215</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M.E., Taub I.B., Kaelber D.C. Risk of myocarditis from COVID-19 infection in people under age 20: A population-based analysis. medRxiv. 2021 doi: 10.1101/2021.07.23.21260998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.23.21260998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>